{"id":"NCT00423488","sponsor":"Organon and Co","briefTitle":"Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)","officialTitle":"A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo Controlled Study Comparing the Efficacy, Safety, and Tolerability of Co-administration of Ezetimibe 10 mg With Ongoing Treatment With Simvastatin 20 mg Versus Doubling the Dose of Simvastatin in Subjects With Primary Hypercholesterolemia Diabetes Mellitus Type 2 and Coronary Heart Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07-12","primaryCompletion":"2007-02-16","completion":"2007-02-16","firstPosted":"2007-01-18","resultsPosted":"2010-03-09","lastUpdate":"2022-02-09"},"enrollment":93,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia","Diabetes Mellitus, Type 2","Coronary Disease"],"interventions":[{"type":"DRUG","name":"Ezetimibe 10 mg","otherNames":[]},{"type":"DRUG","name":"Simvastatin 20 mg","otherNames":[]},{"type":"DRUG","name":"Ezetimibe Placebo","otherNames":[]},{"type":"DRUG","name":"Simvastatin 20 mg","otherNames":[]},{"type":"DRUG","name":"Simvastatin Placebo","otherNames":[]}],"arms":[{"label":"Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg","type":"EXPERIMENTAL"},{"label":"Ezetimibe Placebo + Simvastatin 40 mg","type":"ACTIVE_COMPARATOR"}],"summary":"This multicenter, randomized, double-blind, placebo-controlled study will assess, after 6 weeks of dosing, whether co-administration of ezetimibe 10 mg with simvastatin 20 mg will be more effective than treatment with doubling the dose of simvastatin to 40 mg alone in reducing low-density lipoprotein-cholesterol (LDL-C) concentrations and in achieving the National Cholesterol Expert Panel (NCEP) III LDL-C target goal of \\<2.6 mmol/L (\\<100 mg/dL) for subjects with diabetes mellitus and coronary heart disease.","primaryOutcome":{"measure":"Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Endpoint, After 6 Weeks of Treatment","timeFrame":"6 weeks of treatment (from Baseline to Endpoint)","effectByArm":[{"arm":"Ezetimibe 10 mg + Simvastatin Placebo + Simvastatin 20 mg","deltaMin":-32.2,"sd":15.7},{"arm":"Ezetimibe Placebo + Simvastatin 40 mg","deltaMin":-20.8,"sd":20.1}],"pValues":[{"comp":"OG000 vs OG001","p":"0.005"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":15,"exclusionCount":21},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20492655","20663203"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":40},"commonTop":[]}}